Eiropas Savienība - latviešu - EMA (European Medicines Agency)

advanced accelerator applications - edotreotide - neuroendocrine tumors; radionuclide imaging - diagnostikas radiofarmaceitiskie preparāti - Šīs zāles ir paredzētas tikai diagnostikas vajadzībām. pēc radiolabelling ar gallija (68ga) hlorīda šķīduma risinājums gallija (68ga) edotreotide, ko iegūst, ir norādīts pozitronu emisijas tomogrāfija (pet) attēlveidošanas somatostatin receptoru overexpression pieaugušo pacientiem ar apstiprinātu vai iespējamu labi diferencētas kuņģa-enteropancreatic neiroendokrīnās audzēji (gep-net) par primāro lokalizāciju audzējiem un to metastāzēm.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

advanced accelerator applications - lutecijs (177lu) oksodotreotīds - neiroendokrīnas audzēji - citi terapeitiskie radiofarmaceitiskie preparāti - lutathera ir indicēts attieksmi unresectable vai metastātisku, pakāpenisku, arī diferencēti (g1 un g2), somatostatin receptoru pozitīvu gastroenteropancreatic neuroendocrine audzēju (gep‑nets) pieaugušajiem.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - starojuma radītie bojājumi - detoksikācijas līdzekļi pretvēža terapijai - lysakare ir norādīta samazināšanas nieru starojuma iedarbības laikā peptīdu receptoru radionuklīdu terapija (prrt) ar lutēcijs (177lu) oxodotreotide pieaugušajiem.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

higher nature ltd - tablete

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiski līdzekļi - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiski līdzekļi - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

kapsula

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

a.c.o.m. - advanced center oncology - vara (64cu) hlorīds - radionuklīdu attēlveidošana - citi diagnostiskie radiofarmaceitiskie līdzekļi - cuprymina ir radiofarmaceitiskais prekursors. tas nav paredzēts tiešai lietošanai pacientiem. Šīs zāles jāizmanto tikai pārvadātāja molekulu radioaktīvai iezīmēšanai, kuras ir speciāli izstrādātas un atļautas radioaktīvai marķēšanai ar šo radionuklīdu.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - antineoplastiski līdzekļi - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiski līdzekļi - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.